Burkitt Lymphoma/Leukemia Study
CALGB 10002: Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with G-CSF Support in Previously Untreated Patients with Burkitt Lymphoma/Leukemia
Protocol ID
02-101T
Protocol Description
This research is being done to understand how to improve the treatment of patients with Burkitt lymphoma/leukemia. The purpose of this study is to determine whether adding two new medications (filgrastrim, also known as G-CSF, and rituximab) to a standard treatment and eliminating radiation therapy to the brain improves overall treatment results.
Eligibility Criteria
Patients diagnosed with either Burkitt leukemia or Burkitt lymphoma
Primary Investigator(s)
- Jonathan Kolitz, MD
Contact Information
Last Update
March 26, 2010How did I get to this page?
Persistent Navigation
- Home
- About Us
- Centers of Excellence
- Our Laboratories
- Research Topics
-
Clinical Trials
- Addiction
- Aging
- Allergies
- Arthritis
- Autoimmune Disease
- Blood Disorders
- Cancer
- Children's Health
- Circulation
- Diabetes
- Ear & Hearing
- Eyes
- Gastrointestinal/Hepatitis
- Genetics
- Heart
- HIV
- Infectious Diseases
- Joints
- Kidney
- Lung
- Lupus
- Men's Health
- Mental Health
- Neurosciences
- Radiation Medicine
- Recruitment Registry
- Skin
- Sleep Disorders
- Smoking
- Urinary Tract
- Weight Control
- Women's Health
- Academics
- Resources for Investigators
- Upcoming Events